A-86929

A-86929 is a synthetic compound that acts as a potent and selective dopamine receptor agonist. It was developed by a team of researchers at Abbott Laboratories in the 1990s. A-86929 has been used in scientific research to better understand the role of dopamine receptors in the brain and their potential implications for treating neurological and psychiatric disorders.

Chemistry[edit | edit source]

A-86929 is a member of the benzazepine class of compounds. It is structurally similar to other dopamine agonists such as fenoldopam and SKF-38393, but it is distinguished by its unique substitution pattern on the benzazepine ring. This structural feature is believed to contribute to its high potency and selectivity for dopamine receptors.

Pharmacology[edit | edit source]

A-86929 acts as a full agonist at both D1 and D2 subtypes of dopamine receptors. It has a high affinity for these receptors, which means it can bind to them and activate them very effectively. This makes A-86929 a valuable tool for studying the function of dopamine receptors in the brain.

Clinical significance[edit | edit source]

While A-86929 itself has not been developed as a therapeutic drug, it has been used as a lead compound in the development of other drugs. Most notably, it served as the basis for the design of apomorphine, a drug that is currently used to treat the motor symptoms of Parkinson's disease.